Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data.

Sandeep K Singhal¹, Nawaid Usmani¹, Stefan Michiels^2,3, Otto Metzger-Filho⁴, Kamal S Saini⁵, Olga Kovalchuk^6,7, Matthew Parliament¹

¹Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.

²Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.

³INSERM U1018, CESP, Université Paris-Sud, Villejuif, France.

⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

⁵Quantum Health Analytics SPRL, Liège, Belgium.

⁶Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada.

⁷Canada Cancer and Aging Research Laboratories Ltd., Lethbridge, Canada.

PubMed PMC DOI PDF

Abstract

Until recently, an elevated disease risk has been ascribed to a genetic predisposition, however, exciting progress over the past years has discovered alternate elements of inheritance that involve epigenetic regulation. Epigenetic changes are heritably stable alterations that include DNA methylation, histone modifications and RNA-mediated silencing. Aberrant DNA methylation is a common molecular b…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.